Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ORKA-001

Other · developed by Oruka Therapeutics

Phase 2 Most advanced trial
ORKA Developer
2 Registered trials

What is ORKA-001?

ORKA-001 is an agent given by subcutaneous injection and studied in plaque psoriasis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Dermatology
Developer
Oruka Therapeutics, Inc. (ORKA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
D6ZH4E9SP7

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07449702 Phase 2 Plaque Psoriasis Recruiting ORKA
NCT07090330 Phase 2 Plaque Psoriasis Active not recruiting ORKA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Plaque Psoriasis

More from Oruka Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the ORKA page.

Follow ORKA, the company behind ORKA-001

See ORKA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ORKA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.